Find information on thousands of medical conditions and prescription drugs.

Sulfanilamide

Sulfonamides, also known as sulfa drugs, are synthetic antimicrobial agents derived from sulfonic acid. In bacteria, these drugs are competitive inhibitors of para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. This reaction is necessary in these organisms for the synthesis of folic acid. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
Growth hormone
Salbutamol
Salmeterol
Sandimmune
Sandostatin
Sansert
Saquinavir
Sarafem
Satric
Scopolamine
Seasonale
Secobarbital
Secretin
Selegiline
Semprex-D
Sensipar
Sensorcaine
Serax
Serevent
Serine
Seroquel
Serostim
Serrapeptase
Sertindole
Sertraline
Serzone
Sevelamer
Sevoflurane
Sibutramine
Sildenafil
Silibinin
Simvastatin
Sinemet
Sinequan
Singulair
Sirolimus
Skelaxin
Sodium cyclamate
Solage
Soma
Somatostatin
Sotahexal
Sotalol
Sotret
Spiperone
Spiriva
Spironolactone
Sporahexal
Sporanox
SPS
SSD
Stanozolol
Stavudine
Stelazine
Stilbestrol
Stilbetin
Stimate
Stiripentol
Strattera
Streptokinase
Streptomycin
Suboxone
Subutex
Sucralfate
Sucralfate
Sufentanil
Sulbactam
Sulfamethoxazole
Sulfanilamide
Sulfasalazine
Sulforidazine
Sulla
Sulpiride
Sultamicillin
Sumatriptan
Suprefact
Suramin sodium
Sustaire
Sustiva
Suxamethonium chloride
Symmetrel
Synarel
Synercid
Synthroid
Syntocinon
Zaleplon
T
U
V
W
X
Y
Z

The first sulfonamide was trade named prontosil. The first experiments with prontosil began in 1932 by the German chemist Gerhard Domagk, and the results were published in 1935 (after his employer, IG Farben, had obtained a patent on the compound). Prontosil was a red azo dye, and in mice had a protective action against streptococci. It had no effect in the test tube, and only exerted an antibacterial effect in the live animal itself. And, with war on the horizon, there was interest among the Allies to break the German patent.

Soon it was discovered (1936) that prontosil's active agent was a smaller, more effective compound known as sulfanilamide:

Read more at Wikipedia.org


[List your site here Free!]


CDC surveillance project: gonococcal resistance to quinolones on the rise; National rate increases from 2.2% to 4%
From OB/GYN News, 4/15/04 by Nicholas Mulcahy

PHILADELPHIA -- The rate of fluoroquinolone resistance in Neisseria gonorrhoeae doubled from 2.2% in 2002 to greater than 4% in 2003, and resistant isolates are now surfacing at several sites around the country, according to an official with the Centers for Disease Control and Prevention.

In the past, the problem of quinolone-resistant Neisseria gonorrhoeae (QRNG) was limited to Hawaiii and California, "but we now have big increases in Massachusetts, New Hampshire, New York City, Seattle, and Washington state. We also have increased frequency of resistance to a lesser extent in Chicago, Philadelphia, Las Vegas, and many other cities and states," reported Dr. Susan Wang, national coordinator, gonococcal resistance, in the division of STD prevention at the CDC.

According to preliminary estimates of 2003 data, the national rate of QRNG is about 4%, while the rate is about 12% in Hawaii, 19% in California, and 14% in Massachusetts, she said at a conference on STD prevention sponsored by the CDC.

It's not clear how widespread the problem is, because only a limited number of cities and counties participate in the CDC-sponsored Gonococcal Isolate Surveillance Project (GISP), which monitors the susceptibilities of N. gonorrhoeae strains to antimicrobial agents, including ciprofloxacin and cephalosporins.

"In most places, susceptibility testing is not done at the local level. So you and your local health department may not know if gonococcal resistance is a problem for your area, unless you are in a GISP city," Dr. Wang said.

GISP sites include Albuquerque; Atlanta; Baltimore; Birmingham, Ala.; Chicago; Cincinnati; Cleveland; Dallas; Denver; Detroit; Greensboro, N.C.; Honolulu; Los Angeles; Las Vegas; Long Beach County, Calif.; Miami; Minneapolis; New Orleans; Oklahoma City; Orange County, Calif.; Philadelphia; Phoenix, Ariz.; Portland, Ore.; San Diego; San Francisco; Seattle; and St. Louis.

"The prevalence of QRNG in women is increasing but is generally lower than in men who have sex with men [MSM]," Dr. Wang said. The latter group accounts for a "big portion" of the cases of QRNG. "According to 2002 data, in New York City, Seattle, and Massachusetts, QRNG is especially emerging in MSM," she said.

The lack of data regarding women and QRNG concerns the CDC, Dr. Wang said in an interview. "Data on women are especially important because the long-term sequelae of the disease have the greatest impact on women in terms of pelvic inflammatory disease, infertility, and chronic pelvic pain."

The lack of QRNG data on women is partly a technical issue. The national GISP surveillance system uses N. gonorrhoeae isolates from the first 25 men with gonorrhea attending sexually transmitted diseases clinics at GISP sites each month; the isolates are then sent for testing at regional labs. "GISP surveillance is limited to male urethral specimens in part because these specimens are less complicated to evaluate than female specimens," she said.

The problem of poor data in women and related treatment problems also are worsened by the increasing inability of community-based physicians and labs to perform culture-based testing, Dr. Wang said. "To monitor resistance, you cannot perform DNA-based testing. You need culture-based testing. Physicians and labs increasingly only perform DNA-based testing," she said.

Physicians who believe that a patient is not responding to treatment with a fluoroquinolone should perform a culture and send the sample to a private lab or local health department for susceptibility testing.

For the primary treatment of uncomplicated gonorrhea, the CDC recommends regimens of fluoroquinolones (either single-dose, oral therapy with 500 mg ciprofloxacin or 400 mg ofloxacin or 250 mg levofloxacin); or a single oral dose of cefexime 400 mg; or a 125-mg IM injection of ceftriaxone.

Resistance to ciprofloxacin and other fluoroquinolones limits treatment options because of the current absence of cefixime from the market. "Basically, QRNG threatens the physician's ability to treat with an oral agent. Currently our only other available treatment is a cephalosporin, ceftriaxone, which is an intramuscular injection and doctors may not stock it in private practice," Dr. Wang said.

"Cefixime is also an oral agent and is recommended by the CDC for the treatment of gonorrhea. But it was taken off the market by Wyeth Laboratories in 2002. However, the FDA recently approved a generic manufacturer of cefixime from India to sell the drug here. Cefixime is also an option for QRNG," she said.

Gonococcal resistance has repeatedly occurred in the United States. "Gonococcal resistance has been ongoing since the 1940s, starting with resistance to sulfanilamide. In the 1980s, tetracycline and penicillin were abandoned due to resistance, which led the CDC to recommend treatment with ciprofloxacin or other fluoroquinolones in 1987," Dr. Wang said.

The future treatment of drug-resistant gonorrhea is cloudy, Dr. P. Frederick Sparling observed in his plenary lecture at the meeting. "What drugs will replace ciprofloxacin and cefixime? Pharmaceuticals are abandoning such areas, as they are price-controlled markets, with government as the main buyer. The future of treating gonorrhea is bleak," said Dr. Sparling, J. Herbert Bate Professor of Medicine and Microbiology and Immunology, Emeritus, University of North Carolina at Chapel Hill.

Dr. Sparling added that the implications of emerging vaccines for STDs and attacks from conservative groups on research related to STDs both add to the difficulties in developing new drugs for gonorrhea.

BY NICHOLAS MULCAHY

Contributing Writer

COPYRIGHT 2004 International Medical News Group
COPYRIGHT 2004 Gale Group

Return to Sulfanilamide
Home Contact Resources Exchange Links ebay